We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . . X close

Point of Care Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 2702
Published in Jan, 2025, By MarketsandMarkets™

Choose License Type

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

icon1
USD 22.63 BN
MARKET SIZE, 2030
icon2
CAGR 8.5%
(2025-2030)
icon3
578
REPORT PAGES
icon4
787
MARKET TABLES

OVERVIEW

Point of Care Diagnostics Market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The point of care (POC) diagnostics market is expected to experience substantial growth, rising from USD 15.05 billion in 2024 to USD 22.63 billion by 2029, at a CAGR of 8.5% during the forecast period. This growth is largely driven by the increasing prevalence of chronic diseases such as diabetes and cardiovascular disorders, which demand continuous monitoring, early detection, and timely intervention. The rising need for fast, accurate, and convenient testing solutions has accelerated the adoption of POC diagnostics, particularly glucose monitoring devices, which allow patients and healthcare providers to track health status in real time and manage diseases proactively. Furthermore, supportive government policies, reimbursement initiatives, and growing investments in healthcare innovation are enhancing access to POC technologies, fostering technological advancements, and expanding their integration into clinical and home-care settings. Combined with increasing awareness among patients and clinicians about the benefits of decentralized testing, these factors are contributing to the overall growth and evolution of the POC diagnostics market.

KEY TAKEAWAYS

  • BY PRODUCT
    Based on product, the point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products. The glucose monitoring products segment dominates the market, primarily due to the growing global burden of diabetes. The increasing number of diabetic patients has led to a consistent need for convenient and accurate glucose monitoring devices for effective disease management. Continuous advancements in technology, along with greater accuracy, user-friendliness, and affordability, have further supported the widespread use of glucose monitoring products among both patients and healthcare professionals.
  • BY MODE OF PURCHASE
    The point of care diagnostics market, based on mode of purchase, includes over-the-counter (OTC) testing products and prescription-based testing products. Prescription-based testing products dominate this segment due to their widespread use in clinical environments for the accurate diagnosis and management of chronic and infectious diseases. These tests are typically recommended by healthcare professionals to ensure precise detection and appropriate treatment planning. The growing incidence of conditions such as diabetes, cardiovascular diseases, and infections continues to drive the demand for prescription-based testing. Additionally, compliance with stringent clinical standards and regulatory requirements ensures high-quality outcomes, strengthening their adoption across healthcare systems.
  • BY TECHNOLOGY
    Based on technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. Biochemistry technology holds a significant position in the market, as it is widely used for testing biochemical markers such as glucose, lipids, and electrolytes, which are essential for managing chronic conditions like diabetes, kidney disease, and cardiovascular disorders. Biochemistry-based point of care devices are preferred for their simplicity, rapid results, and cost-effectiveness, making them suitable for both clinical and home-care environments. Additionally, ongoing miniaturization and technological improvements have enhanced their accuracy and ease of use, further driving their adoption across various healthcare settings.
  • BY SAMPLE
    Categorized by sample type, the point of care diagnostics market includes blood samples, urine samples, nasal and oropharyngeal swabs, and other sample types. Blood samples remain a primary choice due to their critical role in detecting a wide range of conditions, including diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and capable of delivering rapid results, making them suitable for both clinical and near-patient settings. Technological advancements have further enhanced efficiency, allowing accurate testing with minimal sample volumes. With the continued rise of chronic and infectious diseases, the demand for rapid, convenient, and reliable blood-based diagnostics continues to drive the preference for this sample type.
  • BY END USER
    Based on end user, the point of care diagnostics market includes clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers and urgent care centers, home care settings and self-testing, and other end users. Home care settings and self-testing are increasingly becoming a key focus as patients seek convenience and comfort, allowing them to monitor their health without frequent visits to healthcare facilities. The rapid availability of results, especially for chronic conditions like diabetes, encourages the use of self-testing devices. Technological advancements have improved accuracy, ease of use, and affordability of home-based tests, enabling individuals with minimal training to perform them effectively. With the rise of chronic diseases and a growing emphasis on preventive care and self-management, home care settings and self-testing continue to drive demand in the point of care diagnostics market.

The point of care diagnostics market is projected to grow significantly in the coming years, driven by the increasing incidence of infectious and chronic diseases that require rapid and continuous monitoring. The growing prevalence of target conditions such as diabetes and cardiovascular disorders is fueling the need for immediate, accurate, and decentralized testing solutions. Additionally, favorable government initiatives promoting POC testing and the rising number of CLIA-waived tests are enhancing accessibility and adoption across healthcare settings. Together, these factors are accelerating the shift toward faster, patient-centered diagnostics and driving overall market growth.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The point of care diagnostics market is influenced by rising healthcare needs and ongoing innovations in rapid testing technologies. Primary users include hospitals, clinics, ambulatory care facilities, urgent care centers, clinical laboratories, and home-care settings, with applications in disease monitoring, early detection, and routine screening. Trends such as increasing prevalence of chronic and infectious diseases, growing adoption of decentralized testing, technological advancements in immunoassays, molecular diagnostics, and biochemistry platforms, and supportive government initiatives are shaping the development, availability, and adoption of POC solutions. These factors drive investments in diagnostic devices, training, and infrastructure, facilitating wider access and faster decision-making in patient care.

Point of Care Diagnostics Market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing incidence of infectious diseases
  • Increasing prevalence of target conditions
RESTRAINTS
Impact
Level
  • Pricing pressure on manufacturers
  • Stringent regulatory approval process for product commercialization
OPPORTUNITIES
Impact
Level
  • Increasing growth potential in emerging markets
  • Rising inclination toward decentralized healthcare system
CHALLENGES
Impact
Level
  • Inadequate standardization with centralized lab methods
  • Limited awareness in emerging markets

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising number of CLIA-waived POC tests

Rising number of CLIA-waived tests is a key driver of the point of care diagnostics market. The simplicity and standardized nature of these tests allow healthcare providers to perform them in a wide range of settings, including clinics, physician offices, urgent care centers, and even home-care environments, without the need for specialized training or complex laboratory infrastructure. This ease of use enables faster turnaround times and immediate availability of results, which is critical for timely diagnosis, treatment decisions, and patient management. As more diagnostic tests receive CLIA-waived status, their adoption increases, supporting market growth and expanding access to efficient, decentralized testing solutions across diverse healthcare settings.

Restraint: Stringent regulatory approval process for product commercialization

Stringent regulatory approval processes act as a significant restraint on the point of care diagnostics market. Because these products are used directly at the point of care, they must adhere to rigorous safety, accuracy, and performance standards to ensure reliable results for patients. Compliance involves comprehensive testing, clinical trials, detailed documentation, and ongoing audits to satisfy regulatory bodies such as the FDA in the US, CE marking in Europe, and other regional authorities. The process is often time-consuming and complex, which can delay product launches, increase development and operational costs, and limit the ability of smaller or new companies to enter the market. Additionally, frequent updates to regulatory requirements in different regions can further complicate commercialization, requiring continuous monitoring and adaptation by manufacturers to maintain compliance.

Opportunity: Rising inclination toward decentralized healthcare system

As healthcare systems shift toward a more decentralized model, there is a growing trend to expand diagnostic capabilities directly to healthcare providers through point of care testing. This allows for faster clinical decision-making by delivering quick and accurate results, improving patient care and enabling timely interventions. Additionally, decentralization supports early detection and management of infectious and chronic diseases, reducing the burden on centralized laboratories. Consequently, this trend is driving increased demand for POC diagnostic solutions, presenting significant growth opportunities for market players.

Challenge: Inadequate standardization with centralized lab methods

Standardization between point of care testing and centralized laboratory methods is one of the major challenges for wider adoption of point of care diagnostics. Point of care tests may be affected by pre-analytical errors due to improper sampling techniques. POC tests are often performed in emergency or high-pressure situations by nurses or other clinical staff rather than trained laboratory personnel, increasing the likelihood of errors that can impact patient care. Additionally, variations in device calibration, assay performance, and result interpretation across different POC platforms further complicate consistency with centralized laboratory standards, limiting full integration into routine clinical workflows.

Point of Care Diagnostics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Provides POC devices for glucose monitoring, infectious disease testing, and cardiometabolic conditions. Rapid results, user-friendly, supports chronic disease management, enables timely clinical decisions.
Offers POC platforms for biochemistry, hematology, and infectious disease testing in hospitals and clinics. Accurate and reliable results, compact and automated systems, improves workflow efficiency, suitable for decentralized care.
Supplies POC diagnostics for molecular testing, immunoassays, and cardiometabolic monitoring. High sensitivity and specificity, fast turnaround time, supports early detection, integrates with clinical workflows.
Provides rapid POC tests for infectious diseases, pregnancy/fertility, and other critical health conditions. Quick results, easy to use, portable platforms, facilitates early diagnosis and timely intervention.
Offers POC instruments and assay kits for infectious diseases, glucose monitoring, and biochemistry testing. Reliable and reproducible results, reduces manual workload, supports decentralized testing, enhances operational efficiency.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The point of care diagnostics market ecosystem comprises device manufacturers, distributors, healthcare providers, clinics, hospitals, and home-care settings working together to deliver rapid and accurate testing. Manufacturers develop solutions for glucose monitoring, infectious disease testing, cardiometabolic monitoring, and other critical health conditions, while distributors ensure timely availability of devices and consumables to healthcare facilities and patients. Primary end users include healthcare professionals, patients, and caregivers, who benefit from quick results, ease of use, and decentralized testing capabilities. Partnerships, regulatory support, and investments in technology are expanding access to POC diagnostics, enabling timely diagnosis, improved patient management, and more efficient healthcare delivery.

Point of Care Diagnostics Market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Point of Care Diagnostics Market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Point of Care Diagnostics Market, By Sample

Categorized by sample type, the point of care diagnostics market includes blood samples, urine samples, nasal and oropharyngeal swabs, and other sample types. Blood samples remain a primary choice due to their critical role in detecting a wide range of conditions, including diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and capable of delivering rapid results, making them suitable for both clinical and near-patient settings. Technological advancements have further enhanced efficiency, allowing accurate testing with minimal sample volumes. With the continued rise of chronic and infectious diseases, the demand for rapid, convenient, and reliable blood-based diagnostics continues to drive the preference for this sample type.

Point of Care Diagnostics Market, By Product

Based on product, the point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products. The glucose monitoring products segment dominates the market, primarily due to the growing global burden of diabetes. The increasing number of diabetic patients has led to a consistent need for convenient and accurate glucose monitoring devices for effective disease management. Continuous advancements in technology, along with greater accuracy, user-friendliness, and affordability, have further supported the widespread use of glucose monitoring products among both patients and healthcare professionals.

Point of Care Diagnostics Market, By Mode of Purchase

The point of care diagnostics market, based on mode of purchase, includes over-the-counter (OTC) testing products and prescription-based testing products. Prescription-based testing products dominate this segment due to their widespread use in clinical environments for the accurate diagnosis and management of chronic and infectious diseases. These tests are typically recommended by healthcare professionals to ensure precise detection and appropriate treatment planning. The growing incidence of conditions such as diabetes, cardiovascular diseases, and infections continues to drive the demand for prescription-based testing. Additionally, compliance with stringent clinical standards and regulatory requirements ensures high-quality outcomes, strengthening their adoption across healthcare systems.

Point of Care Diagnostics Market, By Technology

Based on technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. Biochemistry technology holds a significant position in the market, as it is widely used for testing biochemical markers such as glucose, lipids, and electrolytes, which are essential for managing chronic conditions like diabetes, kidney disease, and cardiovascular disorders. Biochemistry-based point of care devices are preferred for their simplicity, rapid results, and cost-effectiveness, making them suitable for both clinical and home-care environments. Additionally, ongoing miniaturization and technological improvements have enhanced their accuracy and ease of use, further driving their adoption across various healthcare settings.

Point of Care Diagnostics Market, By End User

Based on end user, the point of care diagnostics market includes clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers and urgent care centers, home care settings and self-testing, and other end users. Home care settings and self-testing are increasingly becoming a key focus as patients seek convenience and comfort, allowing them to monitor their health without frequent visits to healthcare facilities. The rapid availability of results, especially for chronic conditions like diabetes, encourages the use of self-testing devices. Technological advancements have improved accuracy, ease of use, and affordability of home-based tests, enabling individuals with minimal training to perform them effectively. With the rise of chronic diseases and a growing emphasis on preventive care and self-management, home care settings and self-testing continue to drive demand in the point of care diagnostics market.

REGION

North America accounted for the largest share of the global point of care diagnostics market during the forecast period.

The point of care diagnostics market in North America is driven by a highly advanced healthcare system, strong infrastructure, and widespread adoption in both clinical and home-care settings. Supportive government initiatives, including funding for healthcare innovations and streamlined regulatory approvals, encourage the development and adoption of new diagnostic technologies. Additionally, robust healthcare research, innovation, and the growing trend of self-testing and at-home healthcare further fuel the demand for point of care diagnostics in the region.

Point of Care Diagnostics Market Region

Point of Care Diagnostics Market: COMPANY EVALUATION MATRIX

Abbott is a leading player in the point of care diagnostics market, providing a wide range of testing solutions for chronic diseases, infectious conditions, and cardiometabolic monitoring. Its platforms are designed for rapid, accurate, and user-friendly testing in both clinical and home-care settings. The company focuses on integrating its devices with digital health tools and data management systems, helping healthcare providers make faster decisions, streamline workflows, and improve patient outcomes.

Point of Care Diagnostics Market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size Value in 2023 USD 14.26 Billion
Revenue Forecast in 2029 USD 22.63 Billion
Growth Rate CAGR of 8.5% from 2024-2029
Actual data 2022-2029
Base year 2023
Forecast period 2024-2029
Units considered Value (USD Million), Volume (Million)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered By product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users)
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis ?  Product matrix, which provides a detailed comparison of the product portfolio of each company in the point of care diagnostics market Enables easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities.
Company Information ?  Additional five company profiles of players operating in the point of care diagnostics market. Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning.
Geographic Analysis ?  Additional country-level analysis of the point of care diagnostics market Guides market entry, localization, and targeted launch strategies by highlighting regional demand and opportunities.

RECENT DEVELOPMENTS

  • June 2024 : bioMérieux (France) received US FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini.
  • June 2024 : F. Hoffmann-La Roche Ltd (Switzerland) acquired LumiraDx’s (US) Point of Care technology to further expand its offering in decentralized patient care and drive global access to timely and actionable diagnostic results.
  • April 2024 : Abbott’s (US) i-STAT TBI cartridge received clearance from the US FDA to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
  • December 2023 : Thermo Fisher Scientific Inc. (US) partnered with Project HOPE, an innovative and leading global health and humanitarian organization, to improve the access to Thermo Fisher HIV testing services amongst the HIV positive youth in Sub-Saharan Africa.
  • April 2023 : BIOSYNEX SA (France) acquired Chembio Diagnostics, Inc. (US) a leading point of care diagnostics company focused on infectious diseases.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
49
RESEARCH METHODOLOGY
55
EXECUTIVE SUMMARY
68
PREMIUM INSIGHTS
74
MARKET OVERVIEW
79
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing incidence of infectious diseases
    - Increasing prevalence of chronic diseases
    - Favorable government initiatives for point of care testing
    - Rising number of waived tests
    RESTRAINTS
    - Pricing pressure on manufacturers
    - Stringent regulatory approval process for product commercialization
    OPPORTUNITIES
    - Increasing growth potential in emerging markets
    - Rising inclination toward decentralized healthcare system
    - Booming healthcare spending worldwide
    CHALLENGES
    - Inadequate standardization with centralized lab methods
    - Premium pricing of novel platforms
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE, BY PRODUCT
    AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
    AVERAGE SELLING PRICE, BY REGION
    - Average selling price of glucose monitoring test strips, by region
    - Average selling price of infectious disease testing products, by region
    - Average selling price of cardiometabolic monitoring products, by region
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Immunoassays
    COMPLEMENTARY TECHNOLOGIES
    - Molecular diagnostics
    ADJACENT TECHNOLOGIES
    - Biochemical technologies
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 3822
    EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
  • 5.16 REGULATORY LANDSCAPE
    REGULATORY ANALYSIS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.17 CASE STUDY ANALYSIS
    CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK
    CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA
    CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS
POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
126
  • 6.1 INTRODUCTION
  • 6.2 GLUCOSE MONITORING PRODUCTS
    GLUCOSE MONITORING STRIPS
    - Growing trend toward preventive healthcare to drive market
    GLUCOSE MONITORING METERS
    - Growing technological advancements in glucose meters to propel market
    GLUCOSE MONITORING LANCETS & LANCING DEVICES
    - Increasing tendency for home-based care and self-monitoring to aid growth
  • 6.3 CARDIOMETABOLIC MONITORING PRODUCTS
    CARDIAC MARKER TESTING PRODUCTS
    - Growing government support for cardiovascular diseases to drive market
    BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
    - Need to optimize hospital workflow to favor growth
    HBA1C TESTING PRODUCTS
    - Increasing recommendations by government healthcare authorities to boost market
  • 6.4 INFECTIOUS DISEASE TESTING PRODUCTS
    RESPIRATORY INFECTION TESTING PRODUCTS
    - Influenza testing products
    - Tuberculosis
    - Other respiratory infection testing products
    HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
    - Growing rate of surgical-site infections to boost market
    TROPICAL DISEASE TESTING PRODUCTS
    - Rising incidence of malaria and dengue to support growth
    SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
    - HIV testing products
    - Hepatitis testing products
    - Syphilis testing products
    - Human papillomavirus testing products
    - Chlamydia trachomatis testing products
    - Neisseria gonorrhea testing products
    - Herpes simplex virus testing products
    CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
    - Rising cases among hospitalized patients to boost demand
    OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.5 COAGULATION MONITORING PRODUCTS
    PT/INR TESTING PRODUCTS
    - Increasing number of atrial fibrillation cases to accelerate growth
    ACT/APTT TESTING PRODUCTS
    - Rise in surgical procedures to speed up growth
  • 6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
    PREGNANCY TESTING PRODUCTS
    - Increasing awareness about family planning to stimulate growth
    FERTILITY TESTING PRODUCTS
    - Growing infertility issues to fuel market
  • 6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
    GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
  • 6.8 URINALYSIS TESTING PRODUCTS
    INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
  • 6.9 CHOLESTEROL TESTING PRODUCTS
    RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
  • 6.10 HEMATOLOGY TESTING PRODUCTS
    INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
  • 6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
    GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
  • 6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
    RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
  • 6.13 FECAL OCCULT TESTING PRODUCTS
    GROWING INCIDENCE OF CANCER TO PROPEL MARKET
  • 6.14 OTHER PRODUCTS
POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
246
  • 7.1 INTRODUCTION
  • 7.2 PRESCRIPTION-BASED TESTING PRODUCTS
    RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
  • 7.3 OTC TESTING PRODUCTS
    GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
255
  • 8.1 INTRODUCTION
  • 8.2 BIOCHEMISTRY
    INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
  • 8.3 IMMUNOASSAYS
    GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
  • 8.4 MOLECULAR DIAGNOSTICS
    RT-PCR
    - Growing use of RT-PCR in proteomics and genomics to boost market
    INAAT
    - Emerging new pathogens to facilitate growth
POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
273
  • 9.1 INTRODUCTION
  • 9.2 BLOOD SAMPLES
    GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
  • 9.3 NASAL & OROPHARYNGEAL SWABS
    INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
  • 9.4 URINE SAMPLES
    NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
  • 9.5 OTHER SAMPLES
POINT OF CARE DIAGNOSTICS MARKET, BY END USER
289
  • 10.1 INTRODUCTION
  • 10.2 HOME CARE SETTINGS AND SELF-TESTING
    INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
  • 10.3 CLINICAL LABORATORIES
    GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
  • 10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
    RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
  • 10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
    NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
  • 10.6 OTHER END USERS
POINT OF CARE DIAGNOSTICS MARKET, BY REGION
305
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth
    CANADA
    - Rising incidence of diabetes and infectious diseases to support growth
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing need for rapid and accurate diagnostic solutions to promote growth
    FRANCE
    - Growing demand for accessible and convenient diagnostic tools to propel market
    UK
    - Rising number of accredited clinical and hospital laboratories to sustain growth
    ITALY
    - Growing burden of infectious and parasitic diseases to boost market
    SPAIN
    - Rising prevalence of circulatory system diseases to contribute to growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing impact of diabetes on public health to amplify growth
    JAPAN
    - Booming geriatric population to stimulate growth
    INDIA
    - Increasing cases of chronic heart and kidney diseases to foster growth
    AUSTRALIA
    - Growing research investments for next-gen point of care devices to boost market
    SOUTH KOREA
    - Growing focus on innovative diagnostic products to drive market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increasing public initiatives in healthcare to encourage growth
    MEXICO
    - Need for frequent testing for disease management to expedite growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.7 GCC COUNTRIES
    BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
COMPETITIVE LANDSCAPE
473
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
  • 12.3 REVENUE ANALYSIS, 2021–2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
    ABBOTT
    F. HOFFMANN-LA ROCHE LTD.
    NOVA BIOMEDICAL
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Mode of purchase footprint
    - Technology footprint
    - Sample footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
  • 12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    DETAILED LIST OF KEY STARTUPS/SMES
    COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 12.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
COMPANY PROFILES
493
  • 13.1 KEY PLAYERS
    ABBOTT
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DANAHER
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    QUIDELORTHO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BD
    - Business overview
    - Products offered
    - Recent developments
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    BIOSYNEX SA
    - Business overview
    - Products offered
    - Recent developments
    EKF DIAGNOSTICS HOLDINGS PLC
    - Business overview
    - Products offered
    - Recent developments
    TRINITY BIOTECH
    - Business overview
    - Products offered
    - Recent developments
    WERFEN
    - Business overview
    - Products offered
    - Recent developments
    NOVA BIOMEDICAL
    - Business overview
    - Products offered
    - Recent developments
    SEKISUI DIAGNOSTICS
    - Business overview
    - Products offered
    BODITECH MED INC.
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    GRIFOLS, S.A.
    LIFESCAN IP HOLDINGS, LLC
    PTS DIAGNOSTICS
    EUROLYSER DIAGNOSTICA GMBH
    RESPONSE BIOMEDICAL
    ALFA SCIENTIFIC DESIGNS, INC.
    BTNX INC.
    ASCENSIA DIABETES CARE HOLDINGS AG
    FLUXERGY
    PRECISION BIOSENSOR, INC.
    ACON LABORATORIES, INC.
    MENARINI DIAGNOSTICS S.R.L
    ORASURE TECHNOLOGIES, INC.
    MANKIND PHARMA
APPENDIX
568
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 POINT OF CARE DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT
  • TABLE 4 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2022 VS. 2035 VS. 2045
  • TABLE 5 GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION, 2021 VS. 2030 VS. 2045 (IN THOUSANDS)
  • TABLE 6 PRODUCT WAIVERS, BY KEY PLAYER, 2021–2024
  • TABLE 7 AVERAGE SELLING PRICE OF POINT OF CARE TESTS, BY PRODUCT, 2022–2024
  • TABLE 8 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2022–2024
  • TABLE 9 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2022–2024
  • TABLE 10 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2024
  • TABLE 11 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022–2024
  • TABLE 12 POINT OF CARE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 13 POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022–2023
  • TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 16 POINT OF CARE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 17 POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY
  • TABLE 20 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 24 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 29 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
  • TABLE 30 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 31 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 32 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
  • TABLE 37 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 38 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
  • TABLE 43 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 44 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
  • TABLE 49 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 KEY CARDIOMETABOLIC MONITORING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 55 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 56 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 67 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 77 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 83 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 89 POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 95 POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 101 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 102 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 KEY HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 107 POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 108 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 113 POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 119 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 120 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 125 POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 129 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 131 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 132 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 135 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 136 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 137 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 138 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 141 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 142 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 143 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 144 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 148 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 149 POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 150 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 153 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 155 POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 156 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 159 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 161 POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 162 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 163 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 164 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 165 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 167 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 170 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 171 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 172 POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 174 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 176 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 177 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 178 POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 179 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 180 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 182 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 183 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 184 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 185 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 186 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 188 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 189 KEY COAGULATION MONITORING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 190 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 191 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 192 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 193 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 195 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 196 POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 197 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 198 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 199 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 200 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 201 POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 202 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 203 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 205 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 206 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 207 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 208 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 209 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 211 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 212 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 213 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 214 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 217 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 218 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 219 POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 220 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 221 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 223 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 224 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
  • TABLE 225 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 226 POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 227 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 228 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 230 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 231 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 232 POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 233 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 234 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 236 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 237 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 238 POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 239 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 240 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 243 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 244 POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 245 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 246 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 247 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 248 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 249 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 250 POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 251 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 252 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 253 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 254 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 255 POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 256 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 257 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 258 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 259 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 260 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 261 POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 262 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 263 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 264 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 265 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 266 KEY OTHER POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 267 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 268 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 269 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 270 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 271 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 272 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 273 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 274 POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 275 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 276 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 278 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 279 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 280 POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 281 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 282 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 283 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 284 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 285 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 286 KEY BIOCHEMISTRY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 287 POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 288 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 289 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 290 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 291 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 292 KEY IMMUNOASSAY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 293 POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 294 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 295 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 296 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 298 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 299 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 300 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 301 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 302 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 303 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 304 KEY RT-PCR-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 305 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 306 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 307 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 308 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 309 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 310 KEY INAAT-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 311 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 312 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 313 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 314 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 315 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 316 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 317 KEY BLOOD SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 318 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 319 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 320 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 321 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 322 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 323 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 324 POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 325 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 326 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 327 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 328 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 329 KEY URINE SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 330 POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 331 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 332 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 333 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 334 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 335 KEY OTHER SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 336 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 337 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 338 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 339 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 340 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 341 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 342 POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 343 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 344 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 345 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 346 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 347 POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 348 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 349 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 350 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 351 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 352 POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 353 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 354 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 355 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 356 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 357 POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 358 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 359 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 360 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 361 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 362 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 363 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 364 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 365 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 366 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 367 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 368 NORTH AMERICA: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 369 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 370 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 371 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 372 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 375 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 376 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 377 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 378 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 379 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 380 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 381 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 383 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 384 NORTH AMERICA: NUMBER OF WOMEN USING HOME PREGNANCY KITS, BY COUNTRY, 2022–2029 (MILLION UNIT)
  • TABLE 385 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 386 US: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 US: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 388 US: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 US: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 390 US: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 391 US: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 392 US: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 393 US: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 394 US: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 395 US: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 396 US: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 397 US: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 398 US: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 399 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 400 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 401 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 402 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 403 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 404 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 405 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 406 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 407 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 408 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 409 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 410 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 411 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 412 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 413 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN EUROPE
  • TABLE 414 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 415 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 416 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 417 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 418 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 419 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 420 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 421 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 422 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 423 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 424 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 425 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 426 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 427 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 428 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 429 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 430 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 431 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 432 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 433 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 434 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 435 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 436 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 438 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 439 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 440 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 441 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 442 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 443 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 444 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 445 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 446 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 447 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 448 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 449 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 450 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 451 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 452 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 453 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 454 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 455 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 456 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 457 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 458 UK: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 459 UK: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 460 UK: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 461 UK: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 462 UK: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 463 UK: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 464 UK: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 465 UK: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 466 UK: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 467 UK: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 468 UK: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 469 UK: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 470 UK: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 471 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 472 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 473 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 474 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 475 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 476 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 477 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 478 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 479 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 480 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 481 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 482 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 483 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 484 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 485 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 486 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 487 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 488 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 489 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 490 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 491 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 492 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 493 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 494 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 495 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 496 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 497 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 498 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 499 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 500 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 501 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 502 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 503 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 504 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 505 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 506 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 507 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 508 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 509 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 510 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 511 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 512 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 513 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 514 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 515 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 516 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 517 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 518 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 519 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 520 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 521 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 522 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 523 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 524 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 525 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 526 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 527 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 528 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 529 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 530 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 531 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 532 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 533 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 534 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 535 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 536 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 537 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 538 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 539 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 540 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 541 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 542 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 543 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 544 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 545 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 546 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 547 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 548 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 549 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 550 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 551 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 552 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 553 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 554 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 555 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 556 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 557 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 558 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 559 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 560 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 561 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 562 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 563 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 564 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 565 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 566 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 567 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 568 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 569 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 570 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 571 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 572 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 573 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 574 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 575 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 576 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 577 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 578 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 579 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 580 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 581 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 582 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 583 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 584 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 585 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 586 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 587 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 588 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 589 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 590 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 591 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 592 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 593 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 594 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 595 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 596 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 597 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 598 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 599 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 600 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 601 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 602 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 603 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 604 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 605 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 606 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 607 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 608 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 609 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 610 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 611 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 612 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 613 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN LATIN AMERICA
  • TABLE 614 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 615 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 616 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 617 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 618 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 619 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 620 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 621 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 622 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 623 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 624 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 625 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 626 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 627 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 628 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 629 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 630 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 631 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 632 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 633 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 634 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 635 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 636 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 637 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 638 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 639 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 640 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 641 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 642 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 643 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 644 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 645 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 646 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 647 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 648 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 649 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 650 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 651 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 652 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 653 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 654 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 655 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 656 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 657 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 658 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 659 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 660 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 661 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 662 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 663 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 664 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 665 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 666 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 667 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 668 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 669 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 670 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 671 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 672 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 673 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 674 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 675 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 676 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 677 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 678 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 679 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 680 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 681 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 682 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 683 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 684 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 685 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 686 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 687 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 688 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 689 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 690 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 691 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 692 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 693 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 694 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 695 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 696 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 697 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 698 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 699 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 700 GCC COUNTRIES: MACROECONOMIC INDICATORS
  • TABLE 701 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021–NOVEMBER 2024
  • TABLE 702 POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 703 POINT OF CARE DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 704 POINT OF CARE DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT
  • TABLE 705 POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 706 POINT OF CARE DIAGNOSTICS MARKET: SAMPLE FOOTPRINT
  • TABLE 707 POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 708 POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 709 POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 710 POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 711 POINT OF CARE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 712 ABBOTT: COMPANY OVERVIEW
  • TABLE 713 ABBOTT: PRODUCTS OFFERED
  • TABLE 714 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 715 ABBOTT: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 716 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 717 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 718 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 719 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 720 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 721 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 722 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 723 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 724 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 725 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 726 DANAHER: COMPANY OVERVIEW
  • TABLE 727 DANAHER: PRODUCTS OFFERED
  • TABLE 728 DANAHER: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 729 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 730 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 731 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 732 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 733 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 734 BD: COMPANY OVERVIEW
  • TABLE 735 BD: PRODUCTS OFFERED
  • TABLE 736 BD: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 737 BD: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 738 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 739 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 740 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 741 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 742 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 743 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 744 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 745 BIOMÉRIEUX: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 746 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 747 BIOSYNEX SA: PRODUCTS OFFERED
  • TABLE 748 BIOSYNEX SA: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 749 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 750 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 751 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 752 EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 753 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 754 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 755 TRINITY BIOTECH: PRODUCTS OFFERED
  • TABLE 756 TRINITY BIOTECH: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 757 TRINITY BIOTECH: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 758 WERFEN: COMPANY OVERVIEW
  • TABLE 759 WERFEN: PRODUCTS OFFERED
  • TABLE 760 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 761 WERFEN: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 762 NOVA BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 763 NOVA BIOMEDICAL: PRODUCTS OFFERED
  • TABLE 764 NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 765 NOVA BIOMEDICAL: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 766 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 767 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 768 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 769 BODITECH MED INC.: PRODUCTS OFFERED
  • TABLE 770 BODITECH MED INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 771 BODITECH MED INC.: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 772 BODITECH MED INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 773 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 774 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
  • TABLE 775 PTS DIAGNOSTICS : COMPANY OVERVIEW
  • TABLE 776 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
  • TABLE 777 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 778 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
  • TABLE 779 BTNX INC.: COMPANY OVERVIEW
  • TABLE 780 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW
  • TABLE 781 FLUXERGY: COMPANY OVERVIEW
  • TABLE 782 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 783 ACON LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 784 MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
  • TABLE 785 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 786 MANKIND PHARMA: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION AND REGIONS COVERED
  • FIGURE 2 POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 9 POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 POINT OF CARE DIAGNOSTICS MARKET: PARAMETRIC ASSUMPTIONS
  • FIGURE 11 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 18 GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 19 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 21 BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 HOME CARE SETTINGS AND SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE IN 2029
  • FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 24 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 REGIONAL INCIDENCE OF HIV, 2023
  • FIGURE 26 NEW REVENUE POCKETS FOR PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
  • FIGURE 27 POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 INVESTMENT AND FUNDING SCENARIO, 2021–2024
  • FIGURE 31 POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2023
  • FIGURE 32 POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
  • FIGURE 34 KEY BUYING CRITERIA, BY TECHNOLOGY
  • FIGURE 35 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
  • FIGURE 36 US: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 37 CANADA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 38 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 39 INDIA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 40 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 41 PREVALENCE OF DIABETES IN IDF REGIONS AMONG 20–79 YEARS OF ADULTS, 2021 VS. 2045 (%)
  • FIGURE 42 PREVALENCE OF HEART AND CIRCULATORY DISEASE WORLDWIDE, 2021 (MILLION)
  • FIGURE 43 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 44 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET 2021–2023
  • FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET, 2023
  • FIGURE 47 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 49 POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 50 POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 51 POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 52 POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 53 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 54 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 55 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 56 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 57 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 58 BD: COMPANY SNAPSHOT (2023)
  • FIGURE 59 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 60 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 61 BIOSYNEX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 62 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 63 TRINITY BIOTECH: COMPANY SNAPSHOT (2023)
  • FIGURE 64 WERFEN: COMPANY SNAPSHOT (2023)

 

Methodology

The study involved major activities in estimating the current market size for the point of care diagnostics market. Exhaustive secondary research was done to collect information on the point of care diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point of care diagnostics market.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Point of Care Diagnostics Market

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

COMPANY NAME DESIGNATION
Abbott Regional Sales Manager
F. Hoffmann-La Roche Ltd Product Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the point of care diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the point of care diagnostics market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Point of Care Diagnostics Market

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Point of care testing (POCT) includes screening or diagnostic tests that are designed to be used at or near the patient's site (such as at home, in an ambulance, at a physician's office, and other locations). POCT allows rapid and reliable diagnostic testing to obtain outcomes instantly, helping physicians/patients make care decisions remotely and as soon as possible.

Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department  
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global point of care diagnostics market, by product, mode of purchase, technology, sample, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall point of care diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East & Africa, and GCC countries
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Key Questions Addressed by the Report

What are the recent trends affecting the point of care diagnostics market?
Recent trends in the point of care diagnostics market include significant technological advancements, rising demand for fast and accurate testing, and the shift towards patient-centered care. The government funding in POC test development and adoption is also picking up, including investments in research, innovation, and infrastructure for new product development, increased accessibility, and reduced costs of testing.
What are the major sample types for point of care diagnostic tests?
Based on sample, the point of care diagnostics market can broadly be divided into blood samples, urine samples, nasal & oropharyngeal swabs, and other samples. Blood samples have dominated the point of care diagnostics market because of their ease of collection, accuracy, and advancements in minimally invasive collection methods such as fingerstick and micro-sampling techniques.
Who are the key players in the point of care diagnostics market?
The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea).
Who are the major end users of point of care diagnostic products?
The point of care diagnostics market is bifurcated into clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users, based on end user. Home care settings and self-testing account for the largest end user segment in the point of care diagnostics market, which is driven by a growing need for convenient, cost-effective, and personalized healthcare solutions.
Which region is lucrative for the point of care diagnostics market?
The Asia Pacific region is one of the most promising regions in the point of care diagnostics market, primarily due to its expanding healthcare infrastructure, increased healthcare expenditure, government initiatives for improving access to healthcare, and awareness of early diagnosis benefits.

Adjacent Markets

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Growth opportunities and latent adjacency in Point of Care Diagnostics Market